Kåre has worn numerous hats throughout his career. From the pharmaceutical industry to CEO at Magle Biopharma, he now leads BII, spearheading the innovative SpaceM project—a pioneering single-cell metabolomics platform.

---

In this discussion, we explore:

1. CEO Aptitude

• What makes a good Biotech CEO?

2. IPO Dynamics

• Many public biotech companies wished they were private in 2022/2023 as stock prices collapsed and market caps fell below cash.
• Pros and cons of going public in volatile markets.

3. Early-Stage Strategic Decision-Making

• Which pivotal parameters should be prioritized to make a project attractive for investment?

…and many more insights from his wealth of experience.

Thanks for watching!

…and many more…